*AURA™ IS PRE-FDA APPROVAL AND NOT YET AVAILABLE. PLEASE SEE THE OFFERING MEMORANDUM’S COMPANY OVERVIEW SECTION FOR INFORMATION REGARDING THE COMPANY’S IP LICENSING AGREEMENTS.
$2,020,017.3
Previously Crowdfunded
$XXX,XXX
Raised in the Current Round
Learn more about investing in Vita Imaging!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By clicking "Stay Updated", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
Reasons to Invest
Turning Subjective Medical Decisions Into Objective Diagnostics, In Seconds
Detect skin cancer in less than 2 seconds
Comprehensive patent portfolio
Non-invasive Raman Spectroscopy technology
Technology platform extensible for use detecting internal organ cancer
*AURA™ is currently undergoing FDA review and is not yet approved for use.
The Problem & Our Solution
5.4 million people are treated for skin cancer yearly.
But current methods for detecting skin cancer are costly, inefficient, and subjective.
That’s why Vita Imaging created AURA: a first-of-its-kind, non-invasive Raman spectroscopy device candidate that can identify benign and malignant lesions in less than 2 seconds. The AURA is currently advancing toward FDA market clearance and preparing for commercial launch after successful testing in comprehensive clinical studies.
The AURA product is pre-FDA approval and is not yet available in the market.
The AURA is so easy it can be operated in just three, non-invasive steps, meaning it can quickly be deployed in any dermatological clinic or healthcare facility.
AURA Development – Past to Present
After $20 million of investment and countless hours of design, engineering, and testing, the AURA™ was created.
To-date, AURA™ has been tested in comprehensive clinical studies – including the largest known study using Raman technology for skin cancer detection – and has successfully passed all product performance and safety tests. Therefore, we believe that AURA™ has strong potential to exceed FDA benchmarks, potentially paving the way for future clearance and commercialization as a Class III medical device, subject to FDA review.
The AURA product is pre-FDA approval and is not yet available in the market.
To our knowledge, this would make AURA™ the first device of its kind to receive FDA clearance, potentially paving the way for broader market adoption.
What Sets Aura Apart from Existing Devices
A high-quality skin cancer detection device requires two properties to be successful:
Sensitivity High sensitivity means less false negative results
Specificity High specificity means less false positive results
While other medical device companies tout their skin cancer diagnostic devices, no product currently on the market matches the AURA’s sensitivity, specificity and testing time in a non-invasive device.
Preliminary data. Aura is not FDA-cleared. Comparisons reflect varying study methods and populations. See offering for details.
Why Invest
A Strong Business Model
Vita Imaging has a quality business model plan ready that is expected to provide the company with solid cash flow from both device sales, recurring revenue, and potential future business opportunities.
We already have exciting plans for the coming years, including:
Expected FDA approval in the second half of 2025
Expansion into additional markets like Australia and the European Union
Development of additional diagnostic devices to detect other forms of cancer
The creation of a comprehensive and valuable spectral imaging database, which can be a strong asset in future company valuation
Our Team
Thinh Tran
CEO & Chairman
Mr. Tran was the Founder, CEO, & Chairman of V-Silicon, a leader in the Smart TV market delivering best in class picture and audio quality. He was previously the Founder, Chairman, & CEO of Sigma Designs since its inception in 1982 which he built from a humble start-up a publicly traded NASDAQ company, at one point was valued at two billion dollars in 2007, before leaving in 2018.
Victoria Reade
COO
Ms. Reade has 25+ years of executive leadership and consulting experience including: Executive Director, MCO Operations & MSO at Scripps Clinic & Green Hospital La Jolla; VP, Medical Management at HMO Pacificare, Healthcare/IT Consultant at Deloitte, TMI, Pharma & Medtech.
Dzung Wright
CFO
Ms. Wright is the Chief Financial Officer of Vita Imaging, Inc. She has over 30 years of experience in the financial industry, holding senior financial positions at multiple publicly traded and startup companies over a wide range of industries such as medical, telecommunications, device technology, digital arts, mobile devices, and internet technology.
Emmeline Braun
Investor Relations
Emmeline specializes in investor relations and media consulting, with a focus on media awareness campaigns and crowdfunding. With a BA in English and a Graduate Diploma in Accounting from UBC Sauder, and experience as the CFO of a publicly traded company, Emmeline combines financial expertise with a keen understanding of investor dynamics to create impactful relationships between companies and their stakeholders.
Invest in a Company That’s Doing Good For the World
Join us and help us create a new standard in medical diagnostics.
Oops! Something went wrong while submitting the form.
By clicking "Stay Updated", you consent to receive marketing text messages (e.g. promos, cart reminders) from StartEngine Crowdfunding, Inc. at the number provided, including messages sent by autodialer. Consent is not a condition of purchase. Msg & data rates may apply. Msg frequency varies. Unsubscribe at any time by replying STOP or clicking the unsubscribe link (where available). Privacy Policy & Terms
Terms
Equity
Offering Minimum
$19,995.60
3,508 shares of Common Stock
Offering Maximum
$4,145,678.40
727,312 shares of Common Stock
Type of Security Offered
Common Stock
Purchase Price of Security Offered
$5.70
Minimum Investment Amount (per investor)
$570.00
*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
Loyalty Bonus
As you are a previous investor, friend, or family member of Vita Imaging Inc., you are eligible for an additional 50% bonus shares.
Time-Based Perks:
Early Bronze: Invest $2,000+ within the first 2 weeks and receive 15% bonus shares ‍Early Silver: Invest $5,000+ within the first 2 weeks and receive 20% bonus shares ‍Early Gold: Invest $10,000+ within the first 2 weeks and receive 25% bonus shares ‍Flash Perk: Invest $2,000+ between day 40 - 45 and receive 10% bonus shares.
Amount-Based Perks:
Bronze: Invest $5,000+ and receive 5% bonus shares ‍Silver: Invest $10,000+ and receive 10% bonus shares ‍Gold: Invest $25,000+ and receive 15% bonus shares ‍Platinum: Invest $50,000+ and receive 20% bonus shares ‍Diamond: Invest $100,000+ and receive 25% bonus shares
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed. Crowdfunding investments made through a self-directed IRA cannot receive perks due to tax laws. The Internal Revenue Service (IRS) prohibits self-dealing transactions in which the investor receives an immediate, personal financial gain on investments owned by their retirement account. As a result, an investor must refuse those perks because they would be receiving a benefit from their IRA account.
The 10% StartEngine Venture Club Bonus
Vita Imaging Inc. will offer 10% additional bonus shares for all investments that are committed by investors who are eligible for the StartEngine Venture Club.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $5.70 / share, you will receive 110 shares of Common Stock, meaning you’ll own 110 shares for $570.00. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor’s eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the Company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed. Eligible investors will also receive the Venture Club Bonus 10%, and the Loyalty Bonus 50% in addition to the aforementioned bonus.
What Is Equity Crowdfunding?​
Equity crowdfunding lets everyday people invest in private companies—like startups or small businesses—and become part-owners.
How it Works
You invest money in a private company (not on the stock market)
You get shares in the company (called “equity”)
If the company grows, your shares may become more valuable
If the company fails, you could lose your investment
What Are Private Companies?
Not listed on the stock market (like Apple or Google)
Usually early-stage or growing businesses
You’re investing early—before most people can
How To Invest?
You invest online through a regulated platform like StartEngine Â
Things to Keep in Mind
These are long-term investments (you might not see returns quickly)
Always read the company’s fundraising page and disclosures
You can lose money—only invest what you can afford
.png)
.png)
